OEA vs PEA – Oleoylethanolamide and Palmitoylethanolamide Compared: PPAR-α Mechanism, Micronized & Liposomal Forms, Purity Grades and Bulk Sourcing Guide

Oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) are the two highest-volume members of the N-acylethanolamide lipid family — built on the same ethanolamide head, differing by one fatty tail. OEA (CAS 111-58-0, an oleoyl C18:1 tail) is a high-affinity PPAR-α satiety signal with an EC50 of 120 nM, sold at 85% and 98% purity. PEA (CAS 544-31-0, a palmitoyl C16:0 tail) is a pro-homeostatic comfort mediator sold at 98% and 99% purity in crystalline, micronized and liposomal grades. One receptor family, two different product categories, and a sourcing decision that hinges on form engineering as much as on the molecule itself.

1. Why OEA and PEA Are Constantly Confused

OEA and PEA share a deceptively similar spec sheet: both are white-to-off-white waxy crystalline powders, both are practically insoluble in water, both activate PPAR-α, both are degraded by fatty acid amide hydrolase (FAAH), and both sit under the same HS heading as acyclic amides. On a crowded supplier list they read like two SKUs of the same thing.

They are not. The difference is one fatty tail and an order of magnitude of receptor potency, and that single difference splits them into two separate product categories with separate customer bases, separate dose ranges, and separate form-engineering economics.

2. Chemical Profiles & Basic Specs

Oleoylethanolamide (OEA)

• Chemical name: (Z)-N-(2-hydroxyethyl)octadec-9-enamide — the ethanolamide of oleic acid; the monounsaturated structural analogue of the endocannabinoid anandamide.
• Appearance: white to off-white crystalline or waxy powder.
• Melting point: reported 59–64 °C depending on supplier and polymorphic history.
• Solubility: soluble in ethanol (to ~35 mg/mL) and DMSO (to ~25 mg/mL); practically insoluble in water; partitions into oils.
• Endogenous identity: produced in the small-intestinal mucosa after fat-rich meals via N-acyltransferase and NAPE-PLD acting on oleoyl-phosphatidylcholine-derived substrate; intestinal levels fall during food deprivation and rise again on refeeding.
• Grades: 85% and 98% (HPLC); bulk packs 1 KG / 5 KG / 10 KG / 25 KG.

Palmitoylethanolamide (PEA, Palmidrol)

• Chemical name: N-(2-hydroxyethyl)hexadecanamide — the ethanolamide of palmitic acid; synonym palmidrol.
• Appearance: white to off-white fine crystalline powder (or micro powder).
• Melting point: reported 97–98.5 °C.
• Solubility: water solubility 4.01 mg/L at 20 °C (practically insoluble); soluble in ethanol and DMSO (to ~25–50 mg/mL); slightly soluble in vegetable oils.
• Endogenous identity: synthesized on demand in the lipid bilayer of stressed or injured tissue; first isolated in the 1950s from egg yolk, peanut meal and soy lecithin fractions with anti-inflammatory activity.
• Grades: 98% and 99% (HPLC) in crystalline, micronized and liposomal forms; bulk packs 1 KG / 5 KG / 10 KG / 25 KG.

3. Mechanism: One Receptor Family, Two Physiologies

Both molecules are ligands of PPAR-α, the nuclear receptor that controls fatty-acid oxidation programs — but they arrive at it with very different force.

• OEA is a nanomolar PPAR-α agonist. In transactivation assays OEA activates PPAR-α with an EC50 of 120 nM, among the tightest endogenous ligands described for this receptor. In preclinical feeding studies, systemic OEA suppresses food intake and weight gain at ~10 mg/kg in wild-type mice, and the effect disappears in PPAR-α knockout animals — the cleanest single-receptor story in the satiety-ingredient space.
• OEA also engages GPR119. At micromolar concentrations OEA activates the lipid receptor GPR119 — the same target class used by metabolic-drug programs — and has been proposed as its endogenous ligand, linking OEA to incretin secretion on the gut–brain axis.
• OEA does not signal through CB1. Despite being anandamide’s monounsaturated cousin, OEA is cannabinoid-receptor-inactive; its metabolic effects are PPAR-α and GPR119 business, not endocannabinoid business.
• PEA is a low-micromolar PPAR-α agent. PEA activates the same nuclear receptor roughly an order of magnitude more weakly than OEA — its pharmacology is not built on receptor potency but on local concentration and tissue context.
• PEA’s signature mechanisms are cellular, not just nuclear. The classical ALIA mechanism (autocoid local injury antagonism, described by Rita Levi-Montalcini in the 1990s) is down-regulation of mast-cell degranulation in injured tissue; the entourage effect is potentiation of local anandamide signalling as PEA competes for FAAH and related hydrolases, raising endocannabinoid tone without binding CB receptors itself.
• PEA modulates glial cells. Published preclinical work shows reduced microglial and astrocyte activation, the basis of the large neuroinflammation-adjacent literature base.

4. Physicochemical Properties

Solubility & Stock Solution Preparation

Both compounds are high-LogP lipids that refuse water. PEA’s measured aqueous solubility is 4.01 mg/L at 20 °C; OEA is effectively insoluble. Useful solvents are ethanol and DMSO for both, with chloroform and warm vegetable oils as formulation-relevant carriers.

• OEA: ethanol to ~35 mg/mL; DMSO to ~25 mg/mL. Solid material is stable ~2 years; stock solutions hold at −20 °C for up to 1 month.
• PEA: ethanol to ~25–50 mg/mL; DMSO to ~25 mg/mL. Solid material is stable ~2 years; solutions hold at −20 °C for up to 3 months.
• Assay work: pre-dissolve in ethanol or DMSO, then dilute into buffered media carrying a low percentage of organic co-solvent (commonly ≤5%) or a protein/cyclodextrin carrier, keeping the lipid in solution through the dilution step.
• Formulation work: micronized PEA disperses as a suspension rather than a solution; liposomal and lipid-dispersion grades exist precisely because neither molecule dissolves usefully in water.

Stability, Melting Point & Storage

• Solid-state stability: both compounds are documented as stable ~2 years at recommended storage; PEA is resistant to hydrolysis at neutral pH but sensitive to strong acid, strong base and sustained temperatures above ~120 °C.
• Storage: tightly closed, cool, dry and dark; −20 °C is the conservative research-stock condition; bulk nutraceutical packs ship in sealed fiber drums with PE liners.
• Melting points: OEA 59–64 °C; PEA 97–98.5 °C. Both values are QC-relevant — a depressed or broad melting range is direct evidence of residual solvents, free fatty acid or unreacted ethanolamine.

5. Side-by-Side Comparison Table

6. Form Engineering: Crystalline vs Micronized vs Liposomal

Because neither molecule dissolves in water, particle engineering is the bioavailability strategy — and it is overwhelmingly a PEA story, because PEA’s effective doses are 4–10× higher than OEA’s, making dissolution-limited absorption the binding constraint on the finished product.

• Crystalline (standard) grade. As-synthesized powder with large, variable particles (native PEA lots can exceed 100 µm). Lowest cost; appropriate when the formulator runs own micronization, or for topical, oral-suspension and research-stock uses.
• Micronized (PEA-m). Air-jet-milled to a D80 around 10 µm; typical commercial specification ≥98% HPLC. The enlarged specific surface area accelerates dissolution in intestinal fluid.
• Ultramicronized (PEA-um). Milled below 10 µm (commonly ~2–6 µm); typical specification ≥99% HPLC. This is the grade behind the published clinical literature on oral PEA.
• Liposomal / lipid-dispersion grade. PEA (and more recently OEA) encapsulated in phospholipid vesicles or solid-lipid / nanostructured carriers, typically sub-micron; exists as liquid dispersions and as powder-in-capsule systems. Cold-water-dispersion systems of the LipiSperse type perform the same job with a surfactant matrix instead of vesicles.

7. Purity Grades Decoded: OEA 85% / 98%, PEA 98% / 99%

The four numbers on the market are not arbitrary — each maps to a feedstock and a purification decision.

OEA 85%

• What it is: oleoylethanolamide at ~85% HPLC assay, produced by amidation of technical-grade oleic acid.
• What the other ~15% is: predominantly the co-amidation products of the fatty-acid impurities in technical oleic acid — stearoylethanolamide (SEA), palmitoylethanolamide itself, and linoleoylethanolamide — plus trace free fatty acid and ethanolamine.
• Why it exists: technical oleic acid is a commodity at ~70–85% cis-oleic content, and the resulting N-acylethanolamide homologues are chromatographically awkward to separate at scale. The 85% grade is the economical weight-management-ingredient workhorse.
• Specification note: a responsible COA states assay and the identity of the homologue impurities — the PEA content of an 85% OEA lot is a number, not a surprise.

OEA 98%

• What it is: high-assay OEA from high-purity oleic acid feedstock or from chromatographic polishing.
• Purchased for: clinical-style finished products, documentation-sensitive markets, and any label claiming a single-molecule OEA content figure.

PEA 98% and 99%

• Feedstock advantage: palmitic acid is a massive commodity available at very high purity, so PEA starts from a cleaner raw material than OEA ever can — which is why PEA’s floor grade is 98% where OEA’s is 85%.
• 98% is the standard fine-powder specification; 99% is the specification tier typically attached to micro / ultramicronized pharma-oriented grades (residue on ignition and heavy-metal limits tighten alongside the assay).
• The purity–form coupling: jet-milling and micronization lines are the same production chain as the 99% assay tier; a 99% COA without particle-size data, or a particle-size COA without a matching assay, is an incomplete spec sheet for this class of material.

8. Application Matching: Which Molecule for Which Product

• Weight-management capsules / appetite-positioned formulas → OEA 98% (or 85% where label economics allow), typically 100–300 mg per day; the PPAR-α / GPR119 satiety story is OEA’s alone.
• Comfort, resilience and nerve-health formulas → PEA ultramicronized 99%, 300–1200 mg per day, aligned with the published clinical literature that uses umPEA.
• Companion-animal (pet) supplements and chews → PEA micronized 98% — the largest single volume channel for PEA outside human supplements.
• Sports-recovery and anti-aging stacks → PEA micronized, frequently stacked with OEA in metabolic-plus-recovery positioning.
• Stick packs, sachets, functional beverages → Liposomal / cold-water-dispersion grades of either molecule; dispersibility is the formulation constraint, and vesicle or surfactant-matrix systems are the only grades that disperse.
• Topical skin-barrier cosmetics → PEA crystalline grade dispersed in the oil phase; both molecules carry cosmetic-function listings (emulsifier / foam-boosting class) from their industrial surfactant past.

9. Regulatory & Export Risk

• OEA, United States: an NDI notification for an OEA-based finished product received an FDA no-objection letter in 2015, and OEA has since been marketed as a dietary-supplement ingredient under DSHEA. NDI no-objection is not drug approval, and it attaches to a specific finished-product notification, not to the molecule at large.
• OEA, European Union: not an authorised novel food — food and functional-food use requires a novel-food authorization pathway; supplement positioning varies by member state. Canada treats it as a Natural Health Product ingredient requiring product-level approval.
• PEA, European Union: decades of marketing history as a food supplement and, in some markets, medical-device-class products; national frameworks differ. PEA, United States: dietary-supplement and pet-supplement channels; not an FDA-approved drug. Neither molecule is an approved drug anywhere in the markets relevant to bulk trade.
• Customs classification: both are acyclic amides with an oxygen function — HS 2924.29 is the chemically correct heading and the common declaration. Some supplier SDS sheets carry 2934.99 (heterocyclic heading); the first shipment in any new lane warrants a broker-confirmed classification before the entries are filed.
• Dangerous-goods layer: both molecules carry H411 (chronic aquatic toxicity) with GHS05/GHS09 pictograms and ship as UN 3077, Class 9, PG III environmentally hazardous solid. Most carriers accept standard service for drum quantities; the DG declaration still appears on the paperwork, and omitting it is a customs-penalty class error.
• Documentation set for B2B lanes: COA with HPLC assay and (for micronized grades) laser-diffraction D-values; SDS matching the GHS05/09 labelling; residual-solvent panel (ICH Q3C) for jet-milled material; heavy-metal panel (Pb, As, Cd, Hg); allergen and GMO statements for supplement customers.

10. Export Volume Ranking (Directional)

A qualitative, directional market view of bulk export volumes across the N-acylethanolamide family — not a published statistic. The ranking reflects dose mass, channel count and years of market presence:

1. Palmitoylethanolamide (PEA) — index 100. The volume leader by a wide margin: human supplement doses up to 1200 mg/day, a large companion-animal channel, topical-cosmetic use, and more than a decade of licensed EU-market products. Micronization capacity is the real bottleneck, which is why ultramicronized 99% carries a premium multiple over crystalline.
2. Oleoylethanolamide (OEA) — index ~15. A fast-growing but narrower base: weight-management capsules at 100–300 mg/day, GLP-1-era tailwind as the “natural satiety” positioning expands, no pet or topical volume to speak of. The 85% grade moves the tonnage; 98% is the documentation tier.
3. The rest of the family (SEA, LEA, DEA and homologues) — negligible as deliberate exports. They move mostly as declared impurities of 85% OEA — which is precisely why the homologue panel on an OEA COA doubles as market intelligence about the seller’s feedstock.

11. Supplier Red Flags When Buying OEA / PEA

1. “Ultramicronized 99%” with no particle-size data on the COA. Jet-milling claims without laser-diffraction D-values (D10/D50/D90) are unverifiable; the premium is being paid for a word, not a distribution.
2. 85% OEA quoted as equivalent to 98%. The 13-point assay gap is mostly other N-acylethanolamides with different regulatory and label implications; the two grades are not interchangeable and not the same price tier.
3. Melting point out of range. An OEA lot melting below ~55 °C or a PEA lot melting below ~90 °C carries free fatty acid, residual solvent or unreacted ethanolamine — a one-instrument QC screen that catches multi-ton problems.
4. No UN 3077 / GHS05+GHS09 on the SDS and DG paperwork. Both molecules are Class 9 environmentally hazardous solids; a “non-hazardous” SDS for either CAS is a compliance defect that surfaces at the first real customs entry.
5. “FDA-approved” or “GRAS-certified” OEA claims. OEA holds an NDI no-objection letter for a specific 2015 notification, not an approval; GRAS is self-affirmation, not certification. Sellers overstating US status export their compliance risk into the buyer’s label.
6. Micronized lots without a residual-solvent panel (ICH Q3C). Jet-milling and classification stages use process solvents and compressed-gas contact; a 99% assay without a solvent panel is half a COA.
7. “Liposomal PEA” that is PEA plus maltodextrin. Genuine liposomal grades document encapsulation — particle size of the carrier, entrapment efficiency, and dispersion behavior in water. A blend sold as liposomal without those three numbers is a marketing grade.
8. COA assay basis unstated. Purity on an as-is basis versus a dry/fatty-acid-free basis can differ by a full percentage point or more at these grades; the assay basis belongs on the COA header.

12. Frequently Asked Questions

13. Final Verdict

PEA is a form-engineering purchase; OEA is a purity-engineering purchase. That is the whole sourcing story in one line.

• Buying OEA means deciding between 85% and 98% — a feedstock and homologue-impurity decision that sets the label claim, the price tier and the regulatory documentation. The molecule arrives as a waxy 60 °C-melting powder and the freight plan respects that.
• Buying PEA means deciding between crystalline, micronized, ultramicronized and liposomal — a particle-engineering decision that determines whether an oral dose works at all, as the rat-model literature demonstrates with same-dose, molecule-identical clarity. Assay barely varies (98/99%); everything that matters is the D-values.

Both belong on the same bench as members of the same lipid family with the same FAAH catabolism, the same ethanolamide head and the same water-insolubility. The moment a purchase order specifies one against the other’s documentation, the mistake is already in the drum. The CAS number — 111-58-0 for OEA, 544-31-0 for PEA — is the first line of the specification, every time.